Showing results (101-110 of 137) with videos related to

Sort By:
Pageof 14
International Journal of Cardiology|April 29, 2019
Recurrent arterial occlusive events in patients with chronic myeloid leukemia treated with second- and third-generation tyrosine kinase inhibitors and role of secondary preventionGiovanni Caocci, Olga Mulas, Massimiliano Bonifacio, et al.
Acta Oncologica (Stockholm, Sweden)|September 9, 2021
Long term follow-up of frontline Dasatinib in older patients with chronic myeloid leukemia in chronic phase treated outside clinical trials: a real-life cohort observational studyFabio Stagno, Massimo Breccia, Mario Annunziata, et al.
Haematologica|June 3, 2017
Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemiaGabriele Gugliotta, Fausto Castagnetti, Massimo Breccia, et al.
Leukemia & Lymphoma|November 6, 2020
Validation and reference values of the EORTC QLQ-CML24 questionnaire to assess health-related quality of life in patients with chronic myeloid leukemiaFabio Efficace, Alessandra Iurlo, Andrea Patriarca, et al.
American Journal of Hematology|March 15, 2016
Rotation of nilotinib and imatinib for first-line treatment of chronic phase chronic myeloid leukemiaGabriele Gugliotta, Fausto Castagnetti, Massimo Breccia, et al.
Annals of Hematology|November 27, 2023
The new Systematic Coronary Risk Evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib or ponatinibOlga Mulas, Elisabetta Abruzzese, Luigiana Luciano, et al.
Hemasphere|November 16, 2020
Integrated Genomic, Functional, and Prognostic Characterization of Atypical Chronic Myeloid LeukemiaDiletta Fontana, Daniele Ramazzotti, Andrea Aroldi, et al.
American Journal of Hematology|October 15, 2013
Long term outcome of Ph+ CML patients achieving complete cytogenetic remission with interferon based therapy moving from interferon to imatinib eraMichele Malagola, Massimo Breccia, Cristina Skert, et al.
Neoplasia (New York, N.Y.)|September 24, 2016
Frontline Dasatinib Treatment in a "Real-Life" Cohort of Patients Older than 65 Years with Chronic Myeloid LeukemiaRoberto Latagliata, Fabio Stagno, Mario Annunziata, et al.
American Journal of Hematology|August 30, 2023
Risk of progression in chronic phase-chronic myeloid leukemia patients eligible for tyrosine kinase inhibitor discontinuation: Final analysis of the TFR-PRO studyGiovanni Paolo Maria Zambrotta, Franck E Nicolini, Sarit Assouline, et al.
Pageof 14